Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Stiefel completes Barrier acquisition

Stiefel completes Barrier acquisition

8th August 2008

Stiefel Laboratories has announced the completion of its acquisition of Barrier Therapeutics.

The company said this strategic deal underlines its dedication to dermatology and to innovation, with the agreement uniting a number of “exciting” assets in the field.

Under the terms of the deal, all outstanding shares of common stock in Barrier have been converted into the right to receive $4.15 (2.15 pounds) and the shares of Barrier have been delisted from the Nasdaq global market.

Stiefel said this acquisition broadens its product offering with three premium prescription products and deepens its product pipeline with the addition of a number of novel drug candidates which will allow the company to leverage its global footprint.

Charles W Stiefel, chairman and chief executive officer of the company, said. “Barrier’s innovative products and pipeline are a very valuable addition to Stiefel.”

He added the acquisition reinforces the company’s pledge to offer high quality, safe, effective and innovative products for the treatment of skin disease.

Mr Stiefel also said the agreement highlights its ongoing dedication to advancing the field of dermatology.

In May 2008, Stiefel announced plans to purchase ABR Invent and ABR Development, the developers of the Atlean dermal filler.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.